The 2016 revised World Health Organization definition of ‘myelodysplastic syndrome with isolated del(5q)’; prognostic implications of single versus double cytogenetic abnormalities

Mark Gurney, Mrinal M Patnaik, Curtis A. Hanson, Mark R Litzow, Aref Al-Kali, Rhett P. Ketterling, Ayalew Tefferi, Naseema Gangat

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

The definition of the myelodysplastic syndrome (MDS) subtype ‘MDS with isolated del(5q)’ was expanded to include cases with one additional non-chromosome 7 based cytogenetic abnormality in the 2016 revised World Health Organization classification. This study applied the revised definition to a large primary MDS cohort, and evaluated the prognostic impact of the additional cytogenetic abnormality. Seventy-two of 1067 patients (7%) met the ‘MDS with isolated del(5q)’ criteria, 11 (1%) of whom had an additional cytogenetic abnormality. There was no survival difference between patients in whom del(5q) occurred alone, compared to those with one additional cytogenetic abnormality (P = 0·52).

Original languageEnglish (US)
Pages (from-to)57-60
Number of pages4
JournalBritish Journal of Haematology
Volume178
Issue number1
DOIs
StatePublished - Jul 1 2017

Keywords

  • cytogenetics
  • deletion 5q
  • myelodysplastic syndrome
  • prognostication

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'The 2016 revised World Health Organization definition of ‘myelodysplastic syndrome with isolated del(5q)’; prognostic implications of single versus double cytogenetic abnormalities'. Together they form a unique fingerprint.

  • Cite this